GI Dynamics, Inc.

Equities

GIDYL

AU000000GID7

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-99.33%

2023	GI Dynamics, Inc. Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India	CI
2022	GI Dynamics, Inc. Announces Final Data from the ENDO Trial, Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity	CI

GI Dynamics, Inc. Appoints Charles Carter as Chief Financial Officer

December 11, 2018 at 04:44 am IST

GI Dynamics, Inc. announced the appointment of Charles Carter to the position of chief financial officer. Carter's role with GI Dynamics will encompass finance, accounting and administrative functions. In addition, he will serve as the Company's treasurer and will replace Dave Bruce as secretary. Carter brings nearly 16 years of experience as a finance executive in the medical industry, having worked with a wide variety of life sciences, therapeutics and medical device companies.

Latest news about GI Dynamics, Inc.

GI Dynamics, Inc. Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India	13/23/13	CI
GI Dynamics, Inc. Announces Final Data from the ENDO Trial, Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity	15/22/15	CI
GI Dynamics Inc. Announces Approval of the I-STEP Clinical Study in India	31/22/31	CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	07/21/07	CI
Gi Dynamics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	12/21/12	CI
GI Dynamics, Inc. Auditor Raises 'Going Concern' Doubt	12/21/12	CI
GI Dynamics, Inc. Announces Termination of Charles Carter as Treasurer and Secretary	16/21/16	CI
GI Dynamics, Inc. Announces Termination of Charles Carter as Chief Financial Officer	16/21/16	CI
Gi Dynamics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	11/20/11	CI
GI Dynamics, Inc. Announces CEO Changes	07/20/07	CI
GI Dynamics, Inc. Announces Management Changes	07/20/07	CI
GI Dynamics, Inc. Announces Executive Changes	27/20/27	CI
GI Dynamics, Inc. Announces the Appointment of Joseph Virgilio as its Chief Operating Officer	16/20/16	CI
Transcript : GI Dynamics, Inc. - Shareholder/Analyst Call	04/20/04
GI Dynamics, Inc. Announces Board Resignations	11/20/11	CI
Gi Dynamics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	08/20/08	CI
GI Dynamics, Inc. announced that it has received $0.5 million in funding from Crystal Amber Asset Management Limited	04/20/04	CI
GI Dynamics, Inc. announced that it expects to receive funding from Crystal Amber Asset Management Limited	03/20/03	CI
GI Dynamics, Inc. announced that it expects to receive $9.25 million in funding from Crystal Amber Asset Management Limited	20/20/20	CI
Transcript : GI Dynamics, Inc. - Shareholder/Analyst Call	21/20/21
GI Dynamics, Inc. announced that it has received $0.75 million in funding from Crystal Amber Asset Management Limited	18/20/18	CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	07/20/07	CI
GI Dynamics, Inc. Enters into Sixth Amendment to the Senior Secured Convertible Promissory Note	01/20/01	CI
GI Dynamics, Inc. Announces Change to Board of Directors	30/20/30	CI
GI Dynamics, Inc. Auditor Raises 'Going Concern' Doubt	27/20/27	CI

Chart GI Dynamics, Inc.

Duration

Period

More charts

Company Profile

GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.

Sector

More about the company